His primary scientific interests are in Molecular biology, Cell culture, Cancer research, Internal medicine and Endocrinology. His Molecular biology research incorporates themes from In vitro, Cancer cell, Frameshift mutation, Trichostatin A and Colchicine. His studies in Cell culture integrate themes in fields like Carcinoembryonic antigen, Cell growth, Pathology, Transforming growth factor and Cell type.
As a part of the same scientific family, Michael G. Brattain mostly works in the field of Transforming growth factor, focusing on Growth inhibition and, on occasion, Secretion. His Cancer research research is multidisciplinary, relying on both Cancer, Colorectal cancer, Protein kinase B, Immunology and Transforming growth factor beta. Michael G. Brattain works mostly in the field of Internal medicine, limiting it down to concerns involving Cellular differentiation and, occasionally, Plasminogen activator, Urokinase receptor, Urokinase and Cell.
Michael G. Brattain spends much of his time researching Cancer research, Molecular biology, Transforming growth factor, Cell culture and Internal medicine. The Cancer research study combines topics in areas such as Cancer, Protein kinase B, Survivin, Apoptosis and Colorectal cancer. Michael G. Brattain studied Molecular biology and Fibronectin that intersect with Laminin and Retinoic acid.
His biological study deals with issues like Autocrine signalling, which deal with fields such as Cell cycle. The concepts of his Cell culture study are interwoven with issues in Receptor, Carcinoembryonic antigen, Cellular differentiation and Cell growth. His Internal medicine study incorporates themes from Endocrinology and Oncology.
His primary areas of investigation include Cancer research, Colorectal cancer, Metastasis, XIAP and Apoptosis. His work carried out in the field of Cancer research brings together such families of science as Protein kinase B, Survivin, Histone deacetylase, Transforming growth factor beta and Kinase. Michael G. Brattain has researched Histone deacetylase in several fields, including Molecular biology and Pancreatic cancer.
He works mostly in the field of Molecular biology, limiting it down to topics relating to Transfection and, in certain cases, Proto-Oncogene Proteins c-akt, as a part of the same area of interest. As part of the same scientific family, Michael G. Brattain usually focuses on In vivo, concentrating on Cell culture and intersecting with TUNEL assay. The study of Internal medicine is intertwined with the study of Endocrinology in a number of ways.
Michael G. Brattain mostly deals with Cancer research, PI3K/AKT/mTOR pathway, Kinase, Survivin and Metastasis. His Cancer research study combines topics from a wide range of disciplines, such as Endocrinology, Apoptosis, Insulin-like growth factor 1 receptor, Internal medicine and Transforming growth factor beta. His research brings together the fields of Cell culture and Apoptosis.
His PI3K/AKT/mTOR pathway study combines topics in areas such as Protein kinase B and Cell growth. The various areas that Michael G. Brattain examines in his Survivin study include Cell, Downregulation and upregulation, Transfection and Cell biology. Michael G. Brattain interconnects Colorectal cancer and Immunology in the investigation of issues within Metastasis.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Inactivation of the Type II TGF-β Receptor in Colon Cancer Cells with Microsatellite Instability
Sanford D Markowitz;Jing Wang;Lois Myeroff;Ramon Parsons.
Heterogeneity of Malignant Cells from a Human Colonic Carcinoma
Michael G. Brattain;W. David Fine;F. Mahnaz Khaled;Jerry Thompson.
Cancer Research (1981)
Mutational Inactivation of Transforming Growth Factor β Receptor Type II in Microsatellite Stable Colon Cancers
William M. Grady;Lois L. Myeroff;Sandra E. Swinler;Ashwani Rajput.
Cancer Research (1999)
Demonstration That Mutation of the Type II Transforming Growth Factor β Receptor Inactivates Its Tumor Suppressor Activity in Replication Error-positive Colon Carcinoma Cells
Jing Wang;LuZhe Sun;Lois Myeroff;Xiaofan Wang.
Journal of Biological Chemistry (1995)
Immunohistochemical Demonstration of Phospho-Akt in High Gleason Grade Prostate Cancer
Shazli N. Malik;Michael Brattain;Paramita M. Ghosh;Dean A. Troyer.
Clinical Cancer Research (2002)
Expression of transforming growth factor beta type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells.
Lu Zhe Sun;Gengfei Wu;James K.V. Willson;Elizabeth Zborowska.
Journal of Biological Chemistry (1994)
Establishment of Mouse Colonic Carcinoma Cell Lines with Different Metastatic Properties
Michael G. Brattain;Janna Strobel-Stevens;David Fine;Maryla Webb.
Cancer Research (1980)
Heterogeneity of human colon carcinoma
M. G. Brattain;A. E. Levine;S. Chakrabarty;L. C. Yeoman.
Cancer and Metastasis Reviews (1984)
Comparison of cytotoxicity and DNA breakage activity of congeners of podophyllotoxin including VP16-213 and VM26: a quantitative structure-activity relationship.
Byron H. Long;Steven T. Musial;Michael G. Brattain.
TGF-beta 1 is an autocrine-negative growth regulator of human colon carcinoma FET cells in vivo as revealed by transfection of an antisense expression vector.
Shaoping Wu;Dan Theodorescu;Robert S. Kerbel;James K V Willson.
Journal of Cell Biology (1992)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: